Associate Professor of Surgery
Division of General Thoracic Surgery
Baylor College of Medicine
Director, Mesothelioma Treatment Center
Baylor St. Luke’s Medical Center


Fellowship at Memorial Sloan-Kettering Cancer Center / New York Presbyterian-Weill Cornell Medical Center
Residency at University of Colorado Denver
General Surgery
MD from Vanderbilt University School of Medicine
BS from Boston College


American Board of Surgery
American Board of Thoracic Surgery

Honors & Awards

2016 NCI Director’s Innovation Award

Professional Interests

Professional Statement

Dr. R. Taylor Ripley, is a nationally recognized, board-certified thoracic surgeon and expert in thoracic surgical oncology specializing in treatment of mesothelioma. In addition to mesothelioma, he practices all facets of general thoracic surgery including infectious lung disease and benign esophageal diseases as well as endobronchial, multidisciplinary management of patients with lung, esophageal, thymic, and other thoracic malignancies. and endoscopic interventions.

Dr. Ripley’s focus on mesothelioma and thoracic oncology extends back over ten years from his studies as a thoracic oncology fellow at the NCI. Dr. Ripley also specializes in robotic surgery to provide minimally invasive approaches to thoracic diseases, for which he will team up with our other robotic thoracic surgeons, Drs. Bryan Burt and Shawn Groth.

Dr. Ripley was an associate professor of surgery in the Thoracic and Oncologic Surgery Branch of the National Cancer Institute (NCI). While at the NIH, Dr. Ripley was awarded the NCI Director’s Innovation Award for targeting specific p53-mutations for the treatment of esophageal adenocarcinoma. He established the Foregut Team at the NIH Clinical Center for the management of patients with esophageal cancer. Additionally, he has been developing a novel assessment of thoracic cancers by profiling mitochondrial pathways, which he will continue with us. Dr. Ripley has lectured nationally and published extensively on his work in the field of thoracic oncology and tumor metabolism. Prior to his faculty appointment at the NCI, Dr. Ripley trained extensively in the care of patients with mesothelioma under world-renowned surgeons during his fellowship at Memorial Sloan-Kettering Cancer Center in New York. Prior to that, Dr. Ripley served his general surgery residency at the University of Colorado, and received his MD degree from Vanderbilt University.

Selected Publications

  • Yuan Xu, Paul L. Feingold, Deborah R. Surman, Kate Brown, Vivek Shukla, Sichuan Xi, Jeremy L, Davis, Jonathan Hernandez, David S. Schrump, R. Taylor Ripley. "Bile Acid and Cigarette Smoke Enhance the Malignant Phenotype of Esophageal Adenocarcinoma by Downregulation of the Mitochondrial Membrane Protein, Uncoupling Protein-2." Oncotarget.
  • Zachary J. Brown, D.O. Jonathan M. Hernandez, M.D. R. Taylor Ripley, M.D. Jeremy Lee Davis, MD. "Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer in the U.S. The Time is Now." J Gastrointest Oncol.
  • Kaitlin C. McLoughlin, John W. Goldin, R. Taylor Ripley. "Biology is King and Continues to Rule." J Thorac Cardiovasc Surg.
  • Winifred M. Lo, M.D., R. Taylor Ripley, M.D.. "EGFR-Mutational Status in Lung Adenocarcinoma: Staging Implications or Continuous Evolution?." J Thorac Cardiovasc Surg.
  • Kaitlin C. McLoughlin, R. Taylor Ripley. "Looks Aren’t Everything but Neither is miRNA Profiling." J Thorac Cardiovasc Surg.
  • Jeremy L. Davis and R. Taylor Ripley. "Post-gastrectomy Syndromes and Nutritional Considerations Following Gastric Surgery." Surgery Clinics of North America.
  • Kaitlin C. McLoughlin, R. Taylor Ripley. "Clinical Nomograms: Is a picture worth a thousand words?." J Thorac Cardiovasc Surg.
  • Feingold PL, Quadri HS, Steinberg SM, Malech HL, Gallin JI, Zerbe CS, Marciano BE, Holland SM, Schrump DS, Ripley RT. "Pulmonary Infections Requiring Thoracic Surgery In Chronic Granulomatous Disease: A 25 Year Single Institution Experience." Journal of Clinical Immunology.
  • R. Taylor Ripley, M.D., Kei Suzuki, M.D., Kay See Tan, Ph.D., Prasad S. Adusumilli, M.D., James Huang, M.D., Bernard J. Park, M.D., Robert J. Downey, M.D., Nabil P. Rizk, M.D., M.S., Valerie W. Rusch, M.D., Manjit Bains, M.D., David R. Jones, M.D.. "Postinduction PET assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer." J Thorac Cardiovasc Surg.
  • Rao M, Atay S, Shukla V, Hong Y, Upham T, Ripley R, Hong J, Zhang M, Reardon E, Fetsch P, Miettinen M, Li X, De Rienzo A, Bueno R, Schrump D. "Mithramycin Depletes Sp1 and Activates p53 to Mediate Senescence and Apoptosis of Pleural Mesothelioma Cells." Clin Cancer Res.